Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I initiation expected in Q425 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases. "We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL-17 antagonist that has demonstrated robust activity against all three therapeutically relevant dimeric forms of the IL-17 ligand in preclinical testing.
The potency of PN-881 in our testing is orders of magnitude better than an anti-IL-17 oral small molecule analog, and better than, or on par with, various approved or developmental stage injectable antibody or nanobody therapeutic agents," said Dinesh V. Patel, PhD, President and CEO of Protagonist. "PN-881 is another example of our expertise with discovery and development of oral peptides.
Earlier this week, we and our partner announced the successful outcome in two separate Phase 3 psoriasis studies with the oral peptide IL-23 receptor antagonist icotrokinra." PN-881 has completed extensive preclinical studies, including oral stabili.
